{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:08:25Z","timestamp":1780484905634,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00393-026-01821-5","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:23:10Z","timestamp":1779110590000},"page":"372-381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neue biomarkerbasierte Diagnostikverfahren","New biomarker-based diagnostic tests"],"prefix":"10.1007","volume":"85","author":[{"given":"Franz","family":"Thiele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Finzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"1821_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-019-0090-4","volume":"2","author":"A Coravos","year":"2019","unstructured":"Coravos\u00a0A, Khozin\u00a0S, Mandl\u00a0KD (2019) Developing and adopting safe and effective digital biomarkers to improve patient outcomes. npj Digit Med 2:14","journal-title":"npj Digit Med"},{"key":"1821_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/rheumatology\/ker358","volume":"51","author":"DS Gibson","year":"2012","unstructured":"Gibson\u00a0DS, Rooney\u00a0ME, Finnegan\u00a0S, Qiu\u00a0J, Thompson\u00a0DC, LaBaer\u00a0J, Pennington\u00a0SR, Duncan\u00a0MW (2012) Biomarkers in rheumatology, now and in the future. Rheumatology 51:423\u2013433","journal-title":"Rheumatology"},{"key":"1821_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1196\/annals.1443.013","volume":"1143","author":"WJ Van Venrooij","year":"2008","unstructured":"Van Venrooij\u00a0WJ, Van Beers\u00a0JJBC, Pruijn\u00a0GJM (2008) Anti-CCP Antibody, a Marker for the Early Detection of Rheumatoid Arthritis. Annals of the New York Academy of Sciences 1143:268\u2013285","journal-title":"Annals of the New York Academy of Sciences"},{"key":"1821_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/rheumatology\/keac229","volume":"62","author":"YT Xu","year":"2022","unstructured":"Xu\u00a0YT, Zhang\u00a0YM, Yang\u00a0HX, Ye\u00a0LF, Chen\u00a0F, Lu\u00a0X, Wang\u00a0GC, Peng\u00a0QL (2022) Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease. Rheumatology 62:397\u2013406","journal-title":"Rheumatology"},{"issue":"6","key":"1821_CR5","first-page":"887","volume":"33","author":"HP Tony","year":"2015","unstructured":"Tony\u00a0HP, Roll\u00a0P, Mei\u00a0HE, Bl\u00fcmner\u00a0E, Straka\u00a0A, Gnuegge\u00a0L, D\u00f6rner\u00a0T, FIRST\/ ReFIRST study teams (2015) Combination of B cell biomarkers as independent predictors of response in patients with rheumatoid arthritis treated with rituximab. Clin Exp Rheumatol 33(6):887\u2013894","journal-title":"Clin Exp Rheumatol"},{"key":"1821_CR6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1136\/annrheumdis-2014-206993","volume":"74","author":"K Raza","year":"2015","unstructured":"Raza\u00a0K, Filer\u00a0A (2015) The therapeutic window of opportunity in rheumatoid arthritis: does it ever close? Ann Rheum Dis 74:793\u2013794","journal-title":"Ann Rheum Dis"},{"key":"1821_CR7","doi-asserted-by":"publisher","DOI":"10.1017\/S1463423623000695","volume":"25","author":"M Salinas","year":"2024","unstructured":"Salinas\u00a0M, Blasco \u00c1, Flores\u00a0E, Minguez\u00a0M, Leiva-Salinas\u00a0C (2024) Double positivity for rheumatoid factor and anti-CCP autoantibodies: improving referral from primary care of patients suspected of having rheumatoid arthritis. Prim Health Care Res Dev 25:e6","journal-title":"Prim Health Care Res Dev"},{"key":"1821_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/qjmed\/hcm015","volume":"100","author":"TB Niewold","year":"2007","unstructured":"Niewold\u00a0TB, Harrison\u00a0MJ, Paget\u00a0SA (2007) Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. QJM 100:193\u2013201","journal-title":"QJM"},{"key":"1821_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-040465","volume":"11","author":"H Kamiya","year":"2021","unstructured":"Kamiya\u00a0H, Panlaqui\u00a0OM (2021) Systematic review and meta-analysis of the risk of rheumatoid arthritis-associated interstitial lung disease related to anti-cyclic citrullinated peptide (CCP) antibody. BMJ Open 11:e040465","journal-title":"BMJ Open"},{"issue":"4","key":"1821_CR10","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s10067-017-3561-5","volume":"36","author":"Y Zhang","year":"2017","unstructured":"Zhang\u00a0Y, Li\u00a0H, Wu\u00a0N, Dong\u00a0X, Zheng\u00a0Y (2017) Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol 36(4):817\u2013823","journal-title":"Clin Rheumatol"},{"key":"1821_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1096866","volume":"13","author":"D Sieghart","year":"2023","unstructured":"Sieghart\u00a0D, Konrad\u00a0C, Swiniarski\u00a0S, Haslacher\u00a0H, Aletaha\u00a0D, Steiner\u00a0G (2023) The diagnostic and prognostic value of IgG and IgA anti-citrullinated protein antibodies in patients with early rheumatoid arthritis. Front Immunol 13:1096866","journal-title":"Front Immunol"},{"key":"1821_CR12","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/annrheumdis-2015-eular.1790","volume":"74","author":"J Sokolove","year":"2015","unstructured":"Sokolove\u00a0J, Schiff\u00a0M, Fleischmann\u00a0R et\u00a0al (2015) Impact of baseline anti-cyclic citrullinated peptide 2 antibody titre on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2\u2011year results from the AMPLE trial. Ann Rheum Dis 74:983\u2013984","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1821_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3899\/jrheum.170007","volume":"45","author":"LR Harrold","year":"2018","unstructured":"Harrold\u00a0LR, Litman\u00a0HJ, Connolly\u00a0SE, Kelly\u00a0S, Hua\u00a0W, Alemao\u00a0E, Rosenblatt\u00a0L, Rebello\u00a0S, Kremer\u00a0JM (2018) Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor\u2011\u03b1 Therapy in Patients with Rheumatoid Arthritis: A\u00a0US National Observational Study. J\u00a0Rheumatol 45(1):32\u201339","journal-title":"J Rheumatol"},{"key":"1821_CR14","doi-asserted-by":"crossref","unstructured":"Wang S, Nair N, Cubuk C, Yap CF, Lau R, Giorli G, Fossati-Jimack L, Plant D, Barton A, Lewis M, Pitzalis C, on behalf of STRAP Collaborative Group (2024) OP0224 INTEGRATION OF DNA METHYLATION INTO MULTI-OMIC ANALYSIS OF SYNOVIAL BIOPSIES FROM THE STRAP RANDOMIZED CLINICAL TRIAL IDENTIFIES PREDICTORS OF RESPONSE TO ANTI-TNF THERAPY IN RHEUMATOID ARTHRITIS. Scientific Abstracts. BMJ Publishing Group Ltd and European League Against Rheumatism, 13.1-13","DOI":"10.1136\/annrheumdis-2024-eular.5357"},{"issue":"6","key":"1821_CR15","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","volume":"28","author":"F Rivellese","year":"2022","unstructured":"Rivellese\u00a0F, Surace\u00a0A, Goldmann\u00a0K, Sciacca\u00a0E, \u00c7ubuk\u00a0C, Giorli\u00a0G, John\u00a0CR, Nerviani\u00a0A, Fossati-Jimack\u00a0L, Thorborn\u00a0G, Ahmed\u00a0M, Prediletto\u00a0E, Church\u00a0SE, Hudson\u00a0BM, Warren\u00a0SE, McKeigue\u00a0PM, Humby\u00a0F, Bombardieri\u00a0M, Barnes\u00a0MR, Lewis\u00a0MJ, Pitzalis\u00a0C, R4RA collaborative group (2022) Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat Med 28(6):1256\u20131268","journal-title":"Nat Med"},{"key":"1821_CR16","doi-asserted-by":"crossref","unstructured":"Bokarewa MI, Erlandsson M, Silfversw\u00e4rd S, Andersson KME, Loman \u00c5, Pullerits R (2024) OP0185 MOLECULAR SIGNATURE IN ARTHRALGIA PATIENTS PREDICTING HIGH RISK FOR ARTHRITIS PROGRESSION. Scientific Abstracts. BMJ Publishing Group Ltd and European League Against Rheumatism, 77\u201377.","DOI":"10.1136\/annrheumdis-2024-eular.4837"},{"key":"1821_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110090","volume":"119","author":"O Zaragoza-Garc\u00eda","year":"2023","unstructured":"Zaragoza-Garc\u00eda\u00a0O, Guti\u00e9rrez-P\u00e9rez\u00a0IA, Brice\u00f1o\u00a0O, Villafan-Bernal\u00a0JR, Navarro-Zarza\u00a0JE, Parra-Rojas\u00a0I, Falf\u00e1n-Valencia\u00a0R, Guzm\u00e1n-Guzm\u00e1n\u00a0IP (2023) IFABP2 as a\u00a0new prognostic biomarker for secondary non-response in rheumatoid arthritis. International Immunopharmacology 119:110090","journal-title":"International Immunopharmacology"},{"issue":"1","key":"1821_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/art.21575","volume":"54","author":"L Klareskog","year":"2006","unstructured":"Klareskog\u00a0L, Stolt\u00a0P, Lundberg\u00a0K, K\u00e4llberg\u00a0H, Bengtsson\u00a0C, Grunewald\u00a0J, R\u00f6nnelid\u00a0J, Harris\u00a0HE, Ulfgren\u00a0AK, Rantap\u00e4\u00e4-Dahlqvist\u00a0S, Eklund\u00a0A, Padyukov\u00a0L, Alfredsson\u00a0L (2006) A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54(1):38\u201346","journal-title":"Arthritis Rheum"},{"key":"1821_CR19","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.berh.2011.02.002","volume":"24","author":"J Zochling","year":"2010","unstructured":"Zochling\u00a0J, Smith\u00a0SMITHEUR (2010) Seronegative spondyloarthritis. Best Practice & Research Clinical Rheumatology 24:747\u2013756","journal-title":"Best Practice & Research Clinical Rheumatology"},{"key":"1821_CR20","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1016\/j.cgh.2023.03.044","volume":"21","author":"V Solitano","year":"2023","unstructured":"Solitano\u00a0V, Facciorusso\u00a0A, McGovern\u00a0DPB, Nguyen\u00a0T, Colman\u00a0RJ, Zou\u00a0L, Boland\u00a0BS, Syversen\u00a0SW, J\u00f8rgensen\u00a0KK, Ma\u00a0C, Armuzzi\u00a0A, Wilson\u00a0A et\u00a0al (2023) HLA-DQA1\u221705 Genotype andImmunogenicity to Tumor Necrosis Factor\u2011\u03b1 Antagonists: A\u00a0Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 21:3019\u20133029.e5","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"1821_CR21","doi-asserted-by":"crossref","unstructured":"Pennington SR, Schwenk J, Bendes A, Rischke S, Gurke R, Hahnefeld L, Kirby B, Coates LC, Coleman O, Waddington J, Zhou R, Wundervald B, et\u00a0al. (2024) OP0308 MULTI-OMICS APPROACH TO THE IDENTIFICATION OF BIOMARKERS FOR PROGRESSION FROM PSORIASIS TO PSORIATIC ARTHRITIS. Scientific Abstracts. BMJ Publishing Group Ltd and European League Against Rheumatism, 112.1-112.","DOI":"10.1136\/annrheumdis-2024-eular.2335"},{"key":"1821_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.934937","volume":"9","author":"I Miyagawa","year":"2022","unstructured":"Miyagawa\u00a0I, Nakayamada\u00a0S, Ueno\u00a0M, Miyazaki\u00a0Y, Ohkubo\u00a0N, Inoue\u00a0Y, Kubo\u00a0S, Tanaka\u00a0Y (2022) Precision medicine based on the phenotypic differences in peripheral T helper cells in patients with psoriatic arthritis: One year follow-up outcomes. Front Med (Lausanne) 9:934937","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"1821_CR23","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1002\/art.37995","volume":"65","author":"MA Petri","year":"2013","unstructured":"Petri\u00a0MA, van Vollenhoven\u00a0RF, Buyon\u00a0J, Levy\u00a0RA, Navarra\u00a0SV, Cervera\u00a0R, Zhong\u00a0ZJ, Freimuth\u00a0WW, BLISS-52 and BLISS-76 Study Groups (2013) Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum 65(8):2143\u20132153","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1821_CR24","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1002\/1529-0131(200110)44:10<2350::AID-ART398>3.0.CO;2-A","volume":"44","author":"A Ho","year":"2001","unstructured":"Ho\u00a0A, Barr\u00a0SG, Magder\u00a0LS, Petri\u00a0M (2001) A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 44(10):2350\u20132357","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1821_CR25","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1136\/ard.62.5.435","volume":"62","author":"C Fiehn","year":"2003","unstructured":"Fiehn\u00a0C, Hajjar\u00a0Y, Mueller\u00a0K, Waldherr\u00a0R, Ho\u00a0AD, Andrassy\u00a0K (2003) Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis 62(5):435\u2013439","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1821_CR26","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/art.42941","volume":"76","author":"A Fava","year":"2024","unstructured":"Fava\u00a0A, Wagner\u00a0CA, Guthridge\u00a0CJ, Kheir\u00a0J, Macwana\u00a0S, DeJager\u00a0W, Gross\u00a0T, Izmirly\u00a0P, Belmont\u00a0HM, Diamond\u00a0B, Davidson\u00a0A, Utz\u00a0PJ, Weisman\u00a0MH, Magder\u00a0LS, Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA\/SLE) Network, Guthridge\u00a0JM, Petri\u00a0M, Buyon\u00a0J, James\u00a0JA (2024) Association of Autoantibody Concentrations and Trajectories With Lupus Nephritis Histologic Features and Treatment Response. Arthritis Rheumatol 76(11):1611\u20131622","journal-title":"Arthritis Rheumatol"},{"key":"1821_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25652","author":"A Fava","year":"2025","unstructured":"Fava\u00a0A, Wagner\u00a0CA, Guthridge\u00a0CJ, Macwana\u00a0S, DeJager\u00a0W, Munroe\u00a0ME, Izmirly\u00a0P, Belmont\u00a0HM, Diamond\u00a0B, Davidson\u00a0A, Utz\u00a0PJ, Weisman\u00a0MH, Carlucci\u00a0PM, Dall\u2019Era\u00a0M, Kalunian\u00a0K, Putterman\u00a0C, Anolik\u00a0J, Barnas\u00a0JL, Wofsy\u00a0D, Kamen\u00a0D, Furie\u00a0RA, Rao\u00a0DA, Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus Network, Petri\u00a0M, Guthridge\u00a0JM, Buyon\u00a0J, James\u00a0JA (2025) Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment. Arthritis Care Res (Hoboken). https:\/\/doi.org\/10.1002\/acr.25652","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1821_CR28","doi-asserted-by":"publisher","first-page":"987","DOI":"10.5604\/17322693.1117543","volume":"68","author":"E Wielosz","year":"2014","unstructured":"Wielosz\u00a0E, Dryglewska\u00a0M, Majdan\u00a0M (2014) Serological profile of patients with systemic sclerosis. Postepy Hig Med Dosw (Online) 68:987\u2013991","journal-title":"Postepy Hig Med Dosw (Online)"},{"issue":"7","key":"1821_CR29","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/art.43120","volume":"77","author":"S Di Donato","year":"2025","unstructured":"Di Donato\u00a0S, Ross\u00a0R, Karanth\u00a0R, Kakkar\u00a0V, De Lorenzis\u00a0E, Bissell\u00a0LA, Clark\u00a0K, Yee\u00a0P, Denton\u00a0CP, Del Galdo\u00a0F (2025) Serum Type I Interferon Score for Prediction of Clinically Meaningful Disease Progression in Limited Cutaneous Systemic Sclerosis. Arthritis Rheumatol 77(7):929\u2013941","journal-title":"Arthritis Rheumatol"},{"key":"1821_CR30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/BOR.0000000000000907","volume":"34","author":"V Kakkar","year":"2022","unstructured":"Kakkar\u00a0V, Assassi\u00a0S, Allanore\u00a0Y, Kuwana\u00a0M, Denton\u00a0CP, Khanna\u00a0D, Del Galdo\u00a0F (2022) Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit. Current Opinion in Rheumatology 34:357\u2013364","journal-title":"Current Opinion in Rheumatology"},{"key":"1821_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.933809","volume":"9","author":"D Feldmann","year":"2023","unstructured":"Feldmann\u00a0D, Jandova\u00a0I, Heilmeier\u00a0U, Kollert\u00a0F, Voll\u00a0RE, Finzel\u00a0S (2023) Inflammatory arthritis in systemic sclerosis is associated with elevated C\u2011reactive protein and requires musculoskeletal ultrasound for reliable detection. Front Med (Lausanne) 9:933809","journal-title":"Front Med (Lausanne)"},{"key":"1821_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1446268","volume":"11","author":"U Heilmeier","year":"2024","unstructured":"Heilmeier\u00a0U, Feldmann\u00a0D, Leynes\u00a0A, Seng\u00a0M, Jandova\u00a0I, Keute\u00a0M, Kollert\u00a0F, Voll\u00a0RE, Finzel\u00a0S (2024) Chronic low-grade inflammation in patients with systemic sclerosis is associated with increased risk for arteriosclerotic cardiovascular disease. Front Med (Lausanne) 11:1446268","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"1821_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1338-5","volume":"19","author":"MK Akmatov","year":"2017","unstructured":"Akmatov\u00a0MK, R\u00f6ber\u00a0N, Ahrens\u00a0W, Flesch-Janys\u00a0D, Fricke\u00a0J, Greiser\u00a0H, G\u00fcnther\u00a0K, Kaaks\u00a0R, Kemmling\u00a0Y, Krone\u00a0B, Linseisen\u00a0J, Meisinger\u00a0C, Moebus\u00a0S, Obi\u00a0N, Guzman\u00a0CA, Conrad\u00a0K, Pessler\u00a0F (2017) Anti-nuclear autoantibodies in the general German population: prevalence and lack of association with selected cardiovascular and metabolic disorders-findings of a multicenter population-based study. Arthritis Res Ther 19(1):127","journal-title":"Arthritis Res Ther"},{"key":"1821_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000799","volume":"10","author":"MJ Wahadat","year":"2023","unstructured":"Wahadat\u00a0MJ, Van Tilburg\u00a0SJ, Mueller\u00a0YM, De Wit\u00a0H, Van Helden-Meeuwsen\u00a0CG, Langerak\u00a0AW, Gruijters\u00a0MJ, Mubarak\u00a0A, Verkaaik\u00a0M, Katsikis\u00a0PD, Versnel\u00a0MA, Kamphuis\u00a0S (2023) Targeted multiomics in childhood-onset SLE reveal distinct biological phenotypes associated with disease activity: results from an explorative study. Lupus Sci Med 10:e000799","journal-title":"Lupus Sci Med"},{"key":"1821_CR35","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.gendis.2022.04.007","volume":"9","author":"J Li","year":"2022","unstructured":"Li\u00a0J, Ming\u00a0Z, Yang\u00a0L, Wang\u00a0T, Liu\u00a0G, Ma\u00a0Q (2022) Long noncoding RNA XIST: Mechanisms for X chromosome inactivation, roles in sex-biased diseases, and therapeutic opportunities. Genes & Diseases 9:1478\u20131492","journal-title":"Genes & Diseases"},{"key":"1821_CR36","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/art.40876","volume":"71","author":"JH Stone","year":"2019","unstructured":"Stone\u00a0JH, Tuckwell\u00a0K, Dimonaco\u00a0S, Klearman\u00a0M, Aringer\u00a0M, Blockmans\u00a0D, Brouwer\u00a0E, Cid\u00a0MC, Dasgupta\u00a0B, Rech\u00a0J, Salvarani\u00a0C, Schulze-Koops\u00a0H et\u00a0al (2019) Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. Arthritis & Rheumatology 71:1329\u20131338","journal-title":"Arthritis & Rheumatology"},{"issue":"12","key":"1821_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103469","volume":"22","author":"A Saut","year":"2023","unstructured":"Saut\u00a0A, Paclet\u00a0MH, Trocm\u00e9\u00a0C, Toussaint\u00a0B, Bocquet\u00a0A, Bouillet\u00a0L, Baillet\u00a0A (2023) Serum calprotectin is a marker of disease activity in Giant cell arteritis. Autoimmun Rev 22(12):103469","journal-title":"Autoimmun Rev"},{"key":"1821_CR38","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez Garc\u00eda A, Bara N, Lucena L\u00f3pez D, Starita Fajardo G, Garc\u00eda De La Torre I, V\u00e1zquez Santos A, Peralta Carrero G, Jimenez Esteban J, Fabregate Fuente RM, Ballester Gonz\u00e1lez R, Rodr\u00edguez-Mart\u00edn E, De Le\u00f3n Contreras P, et\u00a0al. (2024) AB1283 ROLE OF IL-17A IN GIANT CELL ARTERITIS: POTENTIAL USEFULNESS AS A BIOMARKER FOR DISEASE ACTIVITY. Scientific Abstracts. BMJ Publishing Group Ltd and European League Against Rheumatism, 1986\u20131987","DOI":"10.1136\/annrheumdis-2024-eular.4229"},{"issue":"8","key":"1821_CR39","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1093\/rheumatology\/kead015","volume":"62","author":"S Giaglis","year":"2023","unstructured":"Giaglis\u00a0S, Daoudlarian\u00a0D, Thiel\u00a0J, Rizzi\u00a0M, Kyburz\u00a0D, Venhoff\u00a0N, Walker\u00a0UA (2023) Mitochondrial DNA: a\u00a0novel indicator of active inflammation in ANCA-associated vasculitides. Rheumatology (Oxford) 62(8):2930\u20132937","journal-title":"Rheumatology (Oxford)"},{"key":"1821_CR40","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejim.2025.04.002","volume":"136","author":"I Elhani","year":"2025","unstructured":"Elhani\u00a0I, Calas\u00a0L, Bejar\u00a0F, Fautrel\u00a0B, Pieroni\u00a0L, Hentgen\u00a0V, Mertz\u00a0P, Mitrovic\u00a0S, Delplanque\u00a0M, Savey\u00a0L, Georgin-Lavialle\u00a0S (2025) Serum interleukin-18 levels are specifically elevated in auto-inflammatory diseases involving the pyrin inflammasome: A study on 516 patients. Eur J Intern Med 136:82\u201385","journal-title":"Eur J Intern Med"},{"issue":"12","key":"1821_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103920","volume":"24","author":"X Wang","year":"2025","unstructured":"Wang\u00a0X, Luo\u00a0Y, Zhou\u00a0Q, Ma\u00a0J (2025) The roles of S100A8\/A9 and S100A12 in autoimmune diseases: Mechanisms, biomarkers, and therapeutic potential. Autoimmun Rev 24(12):103920","journal-title":"Autoimmun Rev"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01821-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-026-01821-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01821-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:29:08Z","timestamp":1780482548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-026-01821-5"}},"subtitle":["M\u00f6glichkeiten einer fr\u00fchzeitigen und pr\u00e4zisen Diagnose rheumatologischer Erkrankungen","Early and precise diagnosis of rheumatological diseases"],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1821"],"URL":"https:\/\/doi.org\/10.1007\/s00393-026-01821-5","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F.\u00a0Thiele\n                      : A.\u00a0Finanzielle Interessen: F.\u00a0Thiele gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Angestellter Arzt in der Facharztweiterbildung zum Facharzt f\u00fcr Innere Medizin und Rheumatologie, Klinik f\u00fcr Rheumatologie und klinische Immunologie, Universit\u00e4tsklinikum Freiburg, Hugstetter Str. 55, 79106, Freiburg, Deutschland.\n                      S.\u00a0Finzel\n                      : A.\u00a0Finanzielle Interessen: S.\u00a0Finzel gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellte Rheumatologin, Klinik f\u00fcr Rheumatologie und klinische Immunologie, Universit\u00e4tsklinikum Freiburg, Hugstetter Str. 55, 79106, Freiburg, Deutschland. | 2.\u00a0Stellvertreterin AK Bewegungsorgane der DEGUM.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autorinnen und Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}